Literature DB >> 29212704

Performance of Ceftolozane-Tazobactam Etest, MIC Test Strips, and Disk Diffusion Compared to Reference Broth Microdilution for β-Lactam-Resistant Pseudomonas aeruginosa Isolates.

Romney M Humphries1, Janet A Hindler2, Paul Magnano2, Annie Wong-Beringer3, Robert Tibbetts4, Shelley A Miller2.   

Abstract

The performance characteristics of the ceftolozane-tazobactam (C-T) Etest (bioMérieux, Marcy l'Etoile, France), MIC test strips (MTS; Liofilchem, Italy), and disk diffusion (Hardy, Santa Ana, CA) were evaluated for a collection of 308 beta-lactam-resistant isolates of Pseudomonas aeruginosa recovered from three institutions in Los Angeles, CA. Reference testing was performed by the reference broth microdilution (rBMD) method. MIC and disk results were interpreted using Clinical and Laboratory Standards Institute breakpoints. Overall, 72.5% of the isolates were susceptible to C-T by rBMD. Etest and disk diffusion demonstrated acceptable performance, whereas MTS yielded a greater than acceptable percentage of minor errors. Categorical agreement was 96.8% for Etest, 87.0% for MTS, and 92.9% for disk diffusion. No very major errors were observed by any test, and no major errors (ME) were observed by Etest or disk diffusion. Two ME (0.9% of susceptible isolates) were observed by MTS. The incidence of minor errors was 3.2%, 12.3%, and 7.1% for Etest, MTS, and disk diffusion, respectively. Essential agreement (EA) for Etest was excellent, at 97.7%, whereas the MICs obtained by MTS tended to be 1 to 2 dilutions higher than those obtained by rBMD, with an EA of 87.0%.
Copyright © 2018 American Society for Microbiology.

Entities:  

Keywords:  Etest; MIC test strip; categorical agreement; ceftolozane-tazobactam; disk diffusion; major error; susceptibility testing; very major error

Mesh:

Substances:

Year:  2018        PMID: 29212704      PMCID: PMC5824066          DOI: 10.1128/JCM.01633-17

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  9 in total

1.  Ceftolozane/tazobactam activity tested against Gram-negative bacterial isolates from hospitalised patients with pneumonia in US and European medical centres (2012).

Authors:  David J Farrell; Helio S Sader; Robert K Flamm; Ronald N Jones
Journal:  Int J Antimicrob Agents       Date:  2014-03-26       Impact factor: 5.283

2.  Comparison of Etest to Broth Microdilution for Testing of Susceptibility of Pseudomonas aeruginosa to Ceftolozane-Tazobactam.

Authors:  Lauren K Flynt; Michael P Veve; Linoj P Samuel; Robert J Tibbetts
Journal:  J Clin Microbiol       Date:  2016-12-28       Impact factor: 5.948

3.  Multicenter Evaluation of Ceftolozane/Tazobactam for Serious Infections Caused by Carbapenem-Resistant Pseudomonas aeruginosa.

Authors:  Jose M Munita; Samuel L Aitken; William R Miller; Federico Perez; Rossana Rosa; Luis A Shimose; Paola N Lichtenberger; Lilian M Abbo; Rupali Jain; Masayuki Nigo; Audrey Wanger; Rafael Araos; Truc T Tran; Javier Adachi; Robert Rakita; Samuel Shelburne; Robert A Bonomo; Cesar A Arias
Journal:  Clin Infect Dis       Date:  2017-07-01       Impact factor: 9.079

4.  Ceftolozane-Tazobactam Activity against Pseudomonas aeruginosa Clinical Isolates from U.S. Hospitals: Report from the PACTS Antimicrobial Surveillance Program, 2012 to 2015.

Authors:  Dee Shortridge; Mariana Castanheira; Michael A Pfaller; Robert K Flamm
Journal:  Antimicrob Agents Chemother       Date:  2017-06-27       Impact factor: 5.191

5.  Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing urinary tract and intraabdominal infections in Europe: report from an antimicrobial surveillance programme (2012-15).

Authors:  Michael A Pfaller; Matteo Bassetti; Leonard R Duncan; Mariana Castanheira
Journal:  J Antimicrob Chemother       Date:  2017-05-01       Impact factor: 5.790

Review 6.  Ceftazidime/Avibactam and Ceftolozane/Tazobactam: Second-generation β-Lactam/β-Lactamase Inhibitor Combinations.

Authors:  David van Duin; Robert A Bonomo
Journal:  Clin Infect Dis       Date:  2016-04-20       Impact factor: 9.079

7.  Activity of Ceftolozane-Tazobactam and Ceftazidime-Avibactam against Beta-Lactam-Resistant Pseudomonas aeruginosa Isolates.

Authors:  Romney M Humphries; Janet A Hindler; Annie Wong-Beringer; Shelley A Miller
Journal:  Antimicrob Agents Chemother       Date:  2017-11-22       Impact factor: 5.191

8.  Antimicrobial activity of ceftolozane/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011-12).

Authors:  Helio S Sader; David J Farrell; Mariana Castanheira; Robert K Flamm; Ronald N Jones
Journal:  J Antimicrob Chemother       Date:  2014-06-10       Impact factor: 5.790

9.  Activity of ceftolozane/tazobactam against surveillance and 'problem' Enterobacteriaceae, Pseudomonas aeruginosa and non-fermenters from the British Isles.

Authors:  David M Livermore; Shazad Mushtaq; Daniele Meunier; Katie L Hopkins; Robert Hill; Rachael Adkin; Aiysha Chaudhry; Rachel Pike; Peter Staves; Neil Woodford
Journal:  J Antimicrob Chemother       Date:  2017-08-01       Impact factor: 5.790

  9 in total
  11 in total

Review 1.  Considerations and Caveats in Combating ESKAPE Pathogens against Nosocomial Infections.

Authors:  Yu-Xuan Ma; Chen-Yu Wang; Yuan-Yuan Li; Jing Li; Qian-Qian Wan; Ji-Hua Chen; Franklin R Tay; Li-Na Niu
Journal:  Adv Sci (Weinh)       Date:  2019-12-05       Impact factor: 16.806

Review 2.  The Continued Value of Disk Diffusion for Assessing Antimicrobial Susceptibility in Clinical Laboratories: Report from the Clinical and Laboratory Standards Institute Methods Development and Standardization Working Group.

Authors:  Romney M Humphries; Susan Kircher; Andrea Ferrell; Kevin M Krause; Rianna Malherbe; Andre Hsiung; C A Burnham
Journal:  J Clin Microbiol       Date:  2018-07-26       Impact factor: 5.948

3.  Multicenter Evaluation of the Etest Gradient Diffusion Method for Ceftolozane-Tazobactam Susceptibility Testing of Enterobacteriaceae and Pseudomonas aeruginosa.

Authors:  Adam L Bailey; Tom Armstrong; Hari-Prakash Dwivedi; Gerald A Denys; Janet Hindler; Shelley Campeau; Maria Traczewski; Romney Humphries; C A Burnham
Journal:  J Clin Microbiol       Date:  2018-08-27       Impact factor: 5.948

4.  Real-World Performance of Susceptibility Testing for Ceftolozane/Tazobactam against Non-Carbapenemase-Producing Carbapenem-Resistant Pseudomonas aeruginosa.

Authors:  Ayesha Khan; José M Munita; Lina Rivas; Manuel Alcalde-Rico; José R W Martínez; María Victoria Moreno; Pamela Rojas; Aniela Wozniak; Patricia García; Jorge Olivares-Pacheco; William R Miller; Cesar A Arias
Journal:  Antimicrob Agents Chemother       Date:  2021-11-15       Impact factor: 5.938

5.  Antimicrobial Activity of Ceftolozane-Tazobactam and Comparators against Clinical Isolates of Haemophilus influenzae from the United States and Europe.

Authors:  Helio S Sader; Cecilia G Carvalhaes; Leonard R Duncan; Dee Shortridge
Journal:  Antimicrob Agents Chemother       Date:  2020-04-21       Impact factor: 5.191

6.  Evaluation of in vitro activity of ceftazidime/avibactam and ceftolozane/tazobactam against MDR Pseudomonas aeruginosa isolates from Qatar.

Authors:  Mazen A Sid Ahmed; Hamad Abdel Hadi; Abubaker A I Hassan; Sulieman Abu Jarir; Muna A Al-Maslamani; Nahla Omer Eltai; Khalid M Dousa; Andrea M Hujer; Ali A Sultan; Bo Soderquist; Robert A Bonomo; Emad Bashir Ibrahim; Jana Jass; Ali S Omrani
Journal:  J Antimicrob Chemother       Date:  2019-12-01       Impact factor: 5.790

7.  Contemporary analysis of ETEST for antibiotic susceptibility and minimum inhibitory concentration agreement against Pseudomonas aeruginosa from patients with cystic fibrosis.

Authors:  Maxwell J Lasko; Holly K Huse; David P Nicolau; Joseph L Kuti
Journal:  Ann Clin Microbiol Antimicrob       Date:  2021-01-19       Impact factor: 3.944

8.  Association of blaVIM-2, blaPDC-35, blaOXA-10, blaOXA-488 and blaVEB-9 β-Lactamase Genes with Resistance to Ceftazidime-Avibactam and Ceftolozane-Tazobactam in Multidrug-Resistant Pseudomonas aeruginosa.

Authors:  Mazen A Sid Ahmed; Faisal Ahmad Khan; Hamad Abdel Hadi; Sini Skariah; Ali A Sultan; Abdul Salam; Abdul Latif Al Khal; Bo Söderquist; Emad Bashir Ibrahim; Ali S Omrani; Jana Jass
Journal:  Antibiotics (Basel)       Date:  2022-01-19

Review 9.  Antimicrobial Susceptibility Testing: A Comprehensive Review of Currently Used Methods.

Authors:  Ina Gajic; Jovana Kabic; Dusan Kekic; Milos Jovicevic; Marina Milenkovic; Dragana Mitic Culafic; Anika Trudic; Lazar Ranin; Natasa Opavski
Journal:  Antibiotics (Basel)       Date:  2022-03-23

10.  Comparative Evaluation of Vitek 2 and Etest versus Broth Microdilution for Ceftazidime/Avibactam and Ceftolozane/Tazobactam Susceptibility Testing of Enterobacterales and Pseudomonas aeruginosa.

Authors:  Arhodoula Papadomanolaki; Maria Siopi; Polyxeni Karakosta; Sophia Vourli; Spyros Pournaras
Journal:  Antibiotics (Basel)       Date:  2022-06-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.